intoplicine has been researched along with Neoplasms in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 4 (80.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (20.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ilaš, J; Kikelj, D; Skok, Ž; Zidar, N | 1 |
| Burris, HA; Chen, SF; Eckardt, J; Fields, SM; Kuhn, JG; Rothenberg, M; Von Hoff, DD | 1 |
| Abigerges, D; Armand, JP; Bayssas, M; Bissery, MC; Bruno, R; Catimel, G; Chabot, GG; Clavel, M; Klink-Alakl, M | 1 |
| Beijnen, JH; Rodenhuis, S; Rosing, H; ten Bokkel Huinink, WW; van Gijn, R; van Tellingen, O; van Warmerdam, LJ; Vermorken, JB | 1 |
| Bayssas, M; Bruno, R; Kim, J; Klink-Alaki, M; Newman, BM; Newman, RA; Pazdur, R | 1 |
1 review(s) available for intoplicine and Neoplasms
| Article | Year |
|---|---|
Dual Inhibitors of Human DNA Topoisomerase II and Other Cancer-Related Targets.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; DNA Topoisomerases, Type II; Drug Design; HSP90 Heat-Shock Proteins; Humans; Neoplasms; Topoisomerase II Inhibitors; Tubulin Modulators | 2020 |
4 trial(s) available for intoplicine and Neoplasms
| Article | Year |
|---|---|
Preclinical and phase I trials of topoisomerase I inhibitors.
Topics: Antineoplastic Agents; Camptothecin; Cell Line; Female; Humans; Indoles; Irinotecan; Male; Neoplasms; Pyridines; Topoisomerase I Inhibitors; Topotecan; Tumor Cells, Cultured; Tumor Stem Cell Assay | 1994 |
Phase I and pharmacology study of intoplicine (RP 60475; NSC 645008), novel topoisomerase I and II inhibitor, in cancer patients.
Topics: Adult; Aged; Dose-Response Relationship, Drug; Enzyme Inhibitors; Female; Heart; Humans; Indoles; Liver; Male; Middle Aged; Myocardium; Neoplasms; Pyridines; Topoisomerase I Inhibitors | 1996 |
Topoisomerase I/II inhibitor intoplicine administered as a 24 h infusion: phase I and pharmacologic study.
Topics: Adult; Aged; Anemia; Antineoplastic Agents; Dose-Response Relationship, Drug; Female; Half-Life; Hepatic Encephalopathy; Humans; Indoles; Infusions, Intravenous; Liver; Male; Middle Aged; Neoplasms; Phlebitis; Pyridines; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors; Transaminases; Treatment Outcome | 1999 |
Phase I trial of intoplicine (RP 60475) administered as a 72 h infusion every 3 weeks in patients with solid tumors.
Topics: Adult; Aged; Agranulocytosis; Antineoplastic Agents; Area Under Curve; Female; Humans; Indoles; Infusions, Intravenous; Male; Maximum Tolerated Dose; Middle Aged; Nausea; Neoplasms; Pyridines; Treatment Outcome | 1999 |